Vücut total yağ kitlesi ve lipid profilinin kemik mineral yoğunluğu île ilişkisi

Kemik mifıeidi yoğunluğu ile yay doku ve Set un ı ku'ıeblerui düzeyi arasındaki ilişki çok sayıda araştırmaya konu olmuş ancak farklı sonuçlar bildirilmiştir. Çalışmamız, kemik mineral yoğunluğunun serum lipid profili ve toplam yağ doku kitlesi ile ilişkisinin araştırılması amacıyla planlandı. Toplam 29 kadında dual enerji x-ray absorbsiyometri yöntemiyle ölçülen kemik mineral yoğunluğu, toplam yağ doku kitlesi ve serum lipid profili değerlendirildi. T skoru -2.5 ve altında olan 13 kadında t skoru -1.5 ve üzerinde olan 16 kadına göre yağ kitlesi, kolesterol, trigiiserid, LDL, VLDL değerleri daha yüksek, HDL değeri daha düşük bulundu. Ayrıca kolesterol düzeyi KMY değeri ile negatif, yağ kitlesi ve yağ oranı ile pozitif ilişki gösteriyordu. Bu sonuçlara göre vücut toplam yağ kitlesi fazla olan hastalarda kolesterol düzeyinin daha yüksek ve kolesterol düzeyi yüksek olan hastalarda kemik mineral yoğunluğunun daha düşük olduğu ve özellikle menapoz sonrası dönemde hiperlıpideminin kardiyovasküler hastalıkların yanı sıra osteoporoz için de bir risk faktörü olabileceği düşünülebilir.

Fat mass lipid profile and relations to bone mineral density

Various studies have examined bone mineral density and its relation to fat mass, but arrived at contradictory results. Our study were planned to evaluate the connection between bone mineral density, serum lipid profile and fat mass. Total fat mass and bone mineral density were measured by dual energy x-ray absorptiometry in 29 women. Serum lipid profile was also evaluated by routine biochemical methods. Total fat mass, cholesterol, trigiiserid, LDL, VLDL levels were higher and HDL level were lower in patients with t score < -2.5 than in 16 patients with t score > -1.5. Furthermore, cholesterol level was negatively correlated with bone mineral density'and positively correlated with fat mass and percent fat. According to our results, serum total cholesterol .level was higher in patients with higher total fat mass and bone mineral density was lover in patients with hypercholesterolemia.

PDF

___

l.Cole RE. Improving clinical decisions for women at risk of osteoporosis: dual-femur bone mineral density testing. Am J Clin Nutr. 2008;108(6):289-95.
2.Adami S, Braga V, Zamboni M, Gatti D, Rossini M, Bakri J. et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Am J Clin Nutr. 2004;74(2): 136-42
3.Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A. Increased bone turnover in patients with hypercholesterolemia. Clip Chem. 2008;55(l): 143-51.
4.Michael DJ, Jill AK, Judd ER, Patrick FS. Measurement of abdominal and visceral fat with computed tomography and dual-energy x-ray absorptiometry. Am J Clin Nutr. 1995;61:274-278.
5.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499-502.
6.Cummings SR, Bauer DC. Do statins prevent both cardiovascular disease and fracture? JAMA. 2000;283:3255-3257.
7.Parhami F, Mody N, Gharavi N, Ballard AJ, Tintut Y, Demer LL, et al. Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. J Bone Miner Res. 1997;32:17-22.
8.Tintut Y, Morony S, Demer LL. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vase Biol. 2004;4:6-10.
9.Koay MA, Woon PY, Zhang Y, Miles LJ, Duncan EL, Ralston SH, et al. Influence of LRP5 polymorphisms on normal variation in BMD. J Bone Miner Res. 2004; 19:1619-1627.
lO.Afshinnia F, Chacko S, Zahedi T. Association of lower serum cholesterol levels with higher risk of osteoporosis in type 2 diabetes. J Bone Miner Res. 2007;13(6):620-8.
ll.McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? JAMA. 2004;23(l):l-10.
12.Çetinkaya A, Büyükmeşe MA, Çetinu E. Postmenapozal Kadınlarda Kan Lipid Düzeyleri ile Kemik Dansitometri Arasındaki İlişkiler. Tıp Araştırma Dergisi. 2006;4:18-21.
13.Tıkız C, Taneli F, Tüzün Ç. Postmenopozal Osteoporozlu Olgularda Bifosfonat Tedavisinin Kan Lipid Parametreleri Üzerine Etkisi. Türk Fiziksel Tıp ve Rehabilitasyon Dergisi. 2005;ll(l):23-9.
14.Yanık B, Geler Külcü D. Postmenopozal Osteoporozda Raloksifen, Alendronat ve Risedronat Tedavilerinin Lipid Profili Üzerine Olan Etkileri. Türk Fiziksel Tıp ve Rehabilitasyon Dergisi. 2008;54:4-7.
15.Shaffer JR, Kammerer CM, Rainwater DL, O'Leary DH. Decreased bone mineral density is correlated with increased subclinical atherosclerosis in older, but not younger, Mexican American women and men: the San Antonio Family Osteoporosis Study. Calcif Tissue Int. 2007;81(6):430-41.
16.Demer LL. Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. Int J Epidemiol. 2002;31(4):737-41.
17.Parhami F, Morrow AD, Balucan J. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vase Biol. 1997;17:680-87.
18.Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone. 1996; 18:397-403.
19.Tintut Y, Morony S, Demer LL. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vase Biol. 2004;24(2):6-10.
20.Demer LL. Vascular calcification and osteoporosis: inflamatory responses to oxidized lipids. Int J Epidemiol. 2002;31:737-41.
21.Nuzzo V, de Milita AM, Ferraro J, Monaco A, Florio E, Miano P, et al. Analysis of skeletal status by quantitative ultrasonometry in a cohort of postmenopausal women with high blood cholesterol without documented osteoporosis. 2009;35:717-22.